Eisai and Accenture Launch Clinical Data Management in India under Global Outsourcing Agreement
News Feb 14, 2008
Eisai Co., Ltd. and Accenture Japan., Ltd. announced that under the global outsourcing agreement signed between Eisai Medical Research Inc. and Accenture LLC, Accenture will provide Eisai with clinical data management services through its delivery center in Chennai, Tamil Nadu, India.
Starting full operation from February 13, 2008 after 3 weeks trial period, the service will cover Japan, the United States, and Europe. This is the first time a major Japanese pharmaceutical company has outsourced clinical data management services as a Business Process Outsourcing to India.
Clinical data management is a set of operational activities which includes data collection, processing, preparation for analysis, and archiving of clinical trial data. Eisai is working proactively to standardize its' clinical data management process to better deliver safe and effective pharmaceuticals to patients globally.
As part of this, the company is outsourcing data management operations to Accenture's Delivery Center in India where there is a concentration of the resources, expert expertise, and appropriate technology. Going forward, Eisai intends to expand its outsourcing to include electronic data capture (eDC) in order to improve the efficiency and timeliness of data collection and reporting. This provides additional flexibility in resourcing Eisai's activities.
Eisai intends to add value through the realization of its "transformation strategy". The transformation strategy is focused on the transfer of some of the company's primary operational functions to areas with quality technology and high cost effectiveness. As a part of this strategy, Eisai established a manufacturing and research subsidiary in India in December 2007.
Through this new strategic agreement, Eisai takes an additional step toward realization of its transformation. The agreement will enhance its capabilities in global clinical research and development, reduces operational costs, and shortens the development timelines.
Modified Form of Botox Could Replace Opioids as Treatment for Chronic PainNews
A modified form of botulinum toxin gives long-lasting pain relief in mice without adverse effects and, in time, could replace opioid drugs as a safe and effective way of treating chronic pain, according to new research.READ MORE
Key Ingredient in Diabetes Drug Modified to Improve Side EffectsNews
Improved medications for Type 2 diabetes are one step closer thanks to a new discovery reported this week. By modifying the key ingredient in current diabetes drugs, the researchers produced a compound that was effective for hyperglycemia in animal trials, yet without the most problematic side effects of current drugs.READ MORE
Tackling Cancer at Ground Zero: Designer Molecule Inhibits Protein TargetNews
A new molecule designed by University of Adelaide researchers shows great promise for future treatment of many cancers. The new molecule successfully targets a protein that plays a major role in the growth of most cancers.READ MORE